NBTX Nanobiotix
Company Analysis
Latest News
🟢 Nanobiotix is trading 5% up in pre-market amid broader biotech-sector strength
Nanobiotix is trading 5.35% up at $31.29 in pre-market on November 5, 2026, in line with a positive biotech-sector backdrop. - Shares closed at $29.70 on...
🟢 Nanobiotix is trading 5.5% up today as biotech sector gains
Nanobiotix is trading at $30.14, up 5.53%, with broader biotech-sector strength providing the clearest context for the move. - The supplied market context...
🟢 Nanobiotix is trading 5% up in pre-market with no clear company-specific catalyst
Nanobiotix is trading at $30.03, up 5.15% in pre-market on November 4, 2026; no clear company-specific catalyst has been identified. - Its latest listed press...
🟢 Nanobiotix is trading 5% up
Nanobiotix is trading 5.14% up at $29.55 on November 3, 2026, with no company-specific catalyst identified for the rise. - A reported biotech-sector rally,...
🔴 Nanobiotix is trading 10.18% down today after a sharp rebound
Nanobiotix is trading at $28.18, down 10.18%, in a pullback after a sharp rebound. - No clear company-specific announcement was identified for November 2. - A...
🔴 Nanobiotix is trading 8.38% down with no clear catalyst identified
Nanobiotix is trading at $28.74, down 8.38%, with no clear company-specific announcement identified to explain the November 2 move. - The latest prominent...
🔴 Nanobiotix is trading 6% down in pre-market
Nanobiotix is trading 5.99% down at $29.49 in pre-market, with the reason for the decline unclear. - No clear company-specific announcement explaining the...
🔴 Nanobiotix is trading 7.16% down today with no clear company-specific catalyst
Nanobiotix is trading at $31.34, down 7.16% now, with no clear company-specific announcement explaining the October 30 decline. - The latest listed company...
🟢 Nanobiotix is trading 5.7% up in after-hours trading after final Phase 1 melanoma data
Nanobiotix is trading $36.50 (+5.71%) as investors react to final Phase 1 melanoma data presented at ESMO. - The study reported a 41.7% response rate,...
🟢 Nanobiotix is trading 6% up on October 27, 2026, after final Phase 1 melanoma data
Nanobiotix is trading 5.93% up at $33.40 after final Phase 1 melanoma data announced October 24 and presented at ESMO. - Among 24 heavily pretreated patients,...
🟢 Nanobiotix is trading 5% up in pre-market after melanoma study reported 41.7% response rate
Nanobiotix is trading at $33.14, up 5.12% in pre-market after updated Phase 1 melanoma results presented at ESMO. - Among 24 heavily pretreated patients: 41.7%...
🟢 Nanobiotix is trading 5% up today after updated Phase 1 melanoma results
Nanobiotix is trading 5.38% higher at $30.94 on October 26 after updated Phase 1 melanoma results were presented at the ESMO congress. - In 24 heavily...
Nanobiotix Melanoma Data Impress in a Tiny Trial, but Can a 24-Patient Study Justify a $1.5 Billion Bet?
Shares of Nanobiotix surged 47% over five trading days to $31.00, capping a week-long rally sparked by the company's updated Phase 1 melanoma results presented...
🟢 Nanobiotix is trading 5.5% up in pre-market after melanoma study showed 41.7% response rate
Nanobiotix is trading at $31.00, up 5.5% in pre-market on October 26 after reporting updated Phase 1 melanoma data on October 24. - Among 24 heavily...
🟢 Nanobiotix is trading 11% up with no clear catalyst identified
Nanobiotix is trading at $28.58, up 10.65%, with no clear company-specific catalyst identified for the October 22 move. - The latest located company news was...
🟢 Nanobiotix is trading 7.12% up — catalyst remains unclear
Nanobiotix is trading at $28.59, up 7.12%, with the catalyst for the October 22 move remaining unclear. - No new company-specific announcement explaining the...
🟢 Nanobiotix is trading 6.24% up in pre-market as biotech ETF XBI rises
Nanobiotix is trading at $27.44, up 6.24% in pre-market, with biotech-sector strength supporting a sector-led explanation. - Biotech ETF XBI is up 3.64%...
🟢 Nanobiotix is trading 11.1% up today amid broader biotech strength
Nanobiotix is trading at $26.82, up 11.1% on October 21, 2026, with broader biotech strength the clearest available context; no company-specific catalyst was...
🟢 Nanobiotix is trading 6.4% up, amid broader biotech-sector strength
Nanobiotix is trading 6.42% up at $25.69 on October 21, with broader biotech-sector strength providing context rather than a clear company-specific...
🟢 Nanobiotix is trading 5% up in pre-market alongside biotech ETF gains
Nanobiotix is trading 5.29% higher at $25.42 in pre-market on October 21, with biotech-sector strength the likeliest context for the move. - XBI gained 3.64%...